[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 82, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 917304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 50, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 49, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 630312, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 56, "title": "Chief Technical Operations Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thorsten  Graef M.D., Ph.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 60, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Moriarty Ph.D.", "title": "Senior VP of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.73, "open": 3.725, "dayLow": 3.65, "dayHigh": 4.15, "regularMarketPreviousClose": 3.73, "regularMarketOpen": 3.725, "regularMarketDayLow": 3.65, "regularMarketDayHigh": 4.15, "payoutRatio": 0.0, "forwardPE": -1.2028985, "volume": 60192, "regularMarketVolume": 60192, "averageVolume": 72177, "averageVolume10days": 60000, "averageDailyVolume10Day": 60000, "bid": 3.98, "ask": 4.02, "bidSize": 1, "askSize": 1, "marketCap": 100800600, "fiftyTwoWeekLow": 3.37, "fiftyTwoWeekHigh": 17.31, "priceToSalesTrailing12Months": 38.754555, "fiftyDayAverage": 6.997, "twoHundredDayAverage": 10.347549, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -30862288, "profitMargins": 0.0, "floatShares": 4323015, "sharesOutstanding": 24289300, "sharesShort": 1183120, "sharesShortPriorMonth": 1250990, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.048699997, "heldPercentInsiders": 0.20643, "heldPercentInstitutions": 0.91095, "shortRatio": 13.7, "shortPercentOfFloat": 0.049000002, "impliedSharesOutstanding": 24289300, "bookValue": 8.276, "priceToBook": 0.50145, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -61276000, "trailingEps": -2.48, "forwardEps": -3.45, "enterpriseToRevenue": -11.866, "enterpriseToEbitda": 0.527, "52WeekChange": -0.68916667, "SandP52WeekChange": 0.14239466, "quoteType": "EQUITY", "currentPrice": 4.15, "targetHighPrice": 23.0, "targetLowPrice": 18.0, "targetMeanPrice": 21.0, "targetMedianPrice": 21.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 146631008, "totalCashPerShare": 6.037, "ebitda": -58574000, "totalDebt": 14968000, "quickRatio": 11.137, "currentRatio": 11.327, "totalRevenue": 2601000, "debtToEquity": 7.447, "revenuePerShare": 0.485, "grossProfits": 2601000, "operatingCashflow": -51057000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -23.44675, "financialCurrency": "USD", "symbol": "ARTV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1740780606, "regularMarketTime": 1740776402, "exchange": "NGM", "messageBoardId": "finmb_672643147", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": 11.260056, "regularMarketPrice": 4.15, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1721395800000, "postMarketChangePercent": -1.68675, "postMarketPrice": 4.08, "postMarketChange": -0.0700002, "regularMarketChange": 0.42000008, "regularMarketDayRange": "3.65 - 4.15", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 72177, "fiftyTwoWeekLowChange": 0.7800002, "fiftyTwoWeekLowChangePercent": 0.23145407, "fiftyTwoWeekRange": "3.37 - 17.31", "fiftyTwoWeekHighChange": -13.16, "fiftyTwoWeekHighChangePercent": -0.7602542, "fiftyTwoWeekChangePercent": -68.916664, "epsTrailingTwelveMonths": -2.48, "epsForward": -3.45, "epsCurrentYear": -5.08, "priceEpsCurrentYear": -0.81692916, "fiftyDayAverageChange": -2.8470001, "fiftyDayAverageChangePercent": -0.40688866, "twoHundredDayAverageChange": -6.1975493, "twoHundredDayAverageChangePercent": -0.5989388, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-07-19", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "Artiva Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]